Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-marketing surveillance study to evaluate the long-term safety and efficacy of Dimethyl fumarate in Swedish patients with multiple sclerosis

Next Previous
Trial Profile

A post-marketing surveillance study to evaluate the long-term safety and efficacy of Dimethyl fumarate in Swedish patients with multiple sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMSE-5
  • Sponsors Biogen

    • Most Recent Events

    • 28 Oct 2022 Results assessing lymphocyte count profiles following discontinuation of Dimethyl fumarate (DMF) due to lymphopenia in a nationwide Swedish population-based setting presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 24 Feb 2016 New trial record
    • 10 Oct 2015 Results (n=1077) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top